- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
BMS Deals Set to Boost Company's Oncology Pipeline
The deals, with Flexus and Rigel, will add another molecule to the company's immunotherapy pipeline and also provide access to a TGF-beta receptor inhibitor to be used in combination with Yervoy and Opdivo.
Bristol-Myers Squibb Co. announced two deals valued at a total of about $1.6 billion that will further strengthen the drugmaker’s oncology pipeline.
The deals with Flexus Biosciences Inc. and Rigel Pharmaceuticals Inc. will add to Bristol’s portfolio of treatments that use the body’s own immune system to fight cancer. New York-based Bristol has shed units in other areas to focus heavily on a new generation of oncology treatments.
Bristol agreed to acquire closely held Flexus in a deal valued at as much as $1.25 billion, assuming certain development milestones are met, the companies said in a statement Monday. The deal gives Bristol full rights to Flexus’s F001287 immunotherapy, which the company plans to move into human trials in the second half of the year. Current shareholders of Flexus, which is based in San Carlos, California, will be part of a spinoff that will retain its earlier-stage immunotherapies.
Read more: http://bloom.bg/1D4jVhB
Source: Bloomberg
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
